Intercept Pharmaceuticals (ICPT) PT Raised to $217.00

Intercept Pharmaceuticals (NASDAQ:ICPT) had its price objective increased by research analysts at Wedbush from $203.00 to $217.00 in a research note issued to investors on Monday, August 6th. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s target price suggests a potential upside of 94.10% from the company’s current price. Wedbush also issued estimates for Intercept Pharmaceuticals’ Q3 2018 earnings at ($2.72) EPS, Q4 2018 earnings at ($2.64) EPS, Q1 2019 earnings at ($2.63) EPS, Q2 2019 earnings at ($2.46) EPS, Q3 2019 earnings at ($2.23) EPS, Q4 2019 earnings at ($2.02) EPS, FY2019 earnings at ($9.33) EPS, FY2020 earnings at ($4.01) EPS, FY2021 earnings at $6.61 EPS and FY2022 earnings at $18.45 EPS.

Several other analysts have also recently commented on the stock. Goldman Sachs Group upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “buy” rating and boosted their price target for the stock from $46.00 to $157.00 in a research note on Monday, August 6th. Cantor Fitzgerald set a $69.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 2nd. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Finally, ValuEngine downgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 2nd. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Intercept Pharmaceuticals has a consensus rating of “Hold” and an average target price of $123.81.

Shares of ICPT traded up $1.87 during trading hours on Monday, reaching $111.80. 271,800 shares of the stock traded hands, compared to its average volume of 737,660. The company has a debt-to-equity ratio of 2.48, a quick ratio of 6.51 and a current ratio of 6.51. Intercept Pharmaceuticals has a 52-week low of $51.05 and a 52-week high of $121.92. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of -7.77 and a beta of -1.68.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) EPS for the quarter, topping the consensus estimate of ($2.83) by $0.25. The business had revenue of $43.58 million for the quarter, compared to analysts’ expectations of $41.26 million. Intercept Pharmaceuticals had a negative net margin of 215.30% and a negative return on equity of 614.15%. The business’s quarterly revenue was up 41.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.46) EPS. equities research analysts predict that Intercept Pharmaceuticals will post -10.86 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. HL Financial Services LLC grew its stake in Intercept Pharmaceuticals by 4.0% in the 2nd quarter. HL Financial Services LLC now owns 12,499 shares of the biopharmaceutical company’s stock worth $1,049,000 after acquiring an additional 483 shares in the last quarter. Opus Point Partners Management LLC grew its stake in Intercept Pharmaceuticals by 19.0% in the 1st quarter. Opus Point Partners Management LLC now owns 4,496 shares of the biopharmaceutical company’s stock worth $277,000 after acquiring an additional 717 shares in the last quarter. Federated Investors Inc. PA grew its stake in Intercept Pharmaceuticals by 17.9% in the 2nd quarter. Federated Investors Inc. PA now owns 6,765 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 1,025 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Intercept Pharmaceuticals by 18.0% in the 2nd quarter. Janney Montgomery Scott LLC now owns 8,422 shares of the biopharmaceutical company’s stock worth $707,000 after acquiring an additional 1,285 shares in the last quarter. Finally, Swiss National Bank grew its stake in Intercept Pharmaceuticals by 4.5% in the 1st quarter. Swiss National Bank now owns 30,500 shares of the biopharmaceutical company’s stock worth $1,876,000 after acquiring an additional 1,300 shares in the last quarter. Institutional investors and hedge funds own 69.42% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

See Also: Price to Earnings Ratio (PE) Basics

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply